Researcher recording observations beside labeled botanical sample tubes in a laboratory

What Kratom Research Knows, Does Not Know, and Is Still Studying

July 15, 2026 at 1:39 pm

Evidence reviewed: July 15, 2026. This is an educational review of kratom research, not medical advice or a product-use guide.

People consume kratom leaf as chewed fresh leaf, tea, dried powder, or capsules, and they also consume concentrated extracts in tablets, gummies, liquids, and powders. Surveys and Southeast Asian community studies commonly report reasons such as increasing energy or alertness, working through fatigue, managing pain, relaxing, changing mood, or coping with opioid withdrawal. People also report nausea, dizziness, constipation, sweating, sedation, tolerance, dependence, and withdrawal. These reports are part of the evidence, even though they are not approved medical indications and do not predict what every person will experience.

Laboratory and human research gives several of those observations a biological context. Mitragynine and 7-hydroxymitragynine interact with opioid receptors; mitragynine can be converted to 7-hydroxymitragynine during metabolism; orally consumed kratom alkaloids reach human blood; and controlled studies have measured concentration-time patterns, short-term adverse effects, and at least one drug interaction. The evidence is much more specific than “research is limited,” but it is also uneven across products and outcomes.

How the evidence is separated

Cell and animal experiments explain possible mechanisms. Controlled human studies measure what happened after a characterized material was administered under a protocol. Surveys and community research document real-world motivations and experiences. Poison-center, case, and toxicology records identify adverse events and combinations that deserve attention. Each source is useful when its actual finding remains attached to the material and population studied.

The sections below state those findings first and then explain the limitation that materially changes their interpretation. The research-method guide covers study design in greater detail.

What is well established about the plant

Kratom is the common name for Mitragyna speciosa, a tropical tree in the Rubiaceae family. Botanical authorities document its accepted name, taxonomic placement, physical characteristics, and native distribution. That establishes the species as a plant; it does not establish that every powder or extract sold under the word kratom has been authenticated.

Whole plants and intact leaves preserve visible taxonomic evidence. Milled powders, extracts, and finished products retain fewer large-scale features, so identity work may use authenticated references, microscopy, chemical profiles, DNA methods, or several approaches together. The botanical guide covers the living tree, while botanical identity testing explains what different laboratory methods can establish.

Plant material also varies. Genetics, growing conditions, leaf maturity, harvest, drying, storage, and processing can contribute to differences among samples. That variability is a normal reason to characterize the actual research material rather than assume one sample represents an entire market.

What is well established about kratom chemistry

Mitragyna speciosa contains multiple alkaloids. Mitragynine is generally the principal alkaloid reported in dried leaf, while named minor alkaloids can occur in different relative amounts. 7-Hydroxymitragynine is chemically distinct from mitragynine and is generally reported at much lower levels in natural leaf material. Processing, oxidation, enrichment, or formulation can produce profiles that differ substantially from the starting leaf.

Modern chromatography and mass spectrometry can separate, identify, and quantify named compounds when methods, reference standards, and sample preparation are appropriate. Closely related isomers can still be difficult to distinguish, and analytical assignments may be refined when stronger structural evidence becomes available.

A chemical result remains a result about a submitted sample. It does not independently establish botanical identity, contaminants, long-term stability, clinical effects, or legal status. The kratom alkaloid guide explains compounds, methods, reporting limits, and units in detail.

Receptor pharmacology, metabolism, and animal findings

In human-receptor cell assays, mitragynine and 7-hydroxymitragynine have acted as partial agonists at the mu-opioid receptor. Some assay systems found G-protein signaling without measurable beta-arrestin recruitment. That signaling profile helped generate interest in “atypical” opioid pharmacology, but it is not evidence that kratom or 7-OH cannot suppress breathing or produce other opioid-related risks in people.

7-Hydroxymitragynine generally shows greater mu-opioid-receptor potency than mitragynine. Mouse studies have reported antinociception—the reduction of responses to a painful stimulus—and slowed gastrointestinal transit after 7-OH administration. Other animal work has examined self-administration, drug discrimination, tolerance, dependence-related behavior, locomotion, and temperature. The results change with compound, route, species, and experimental design.

Metabolism adds another layer. Human and mouse liver preparations convert mitragynine to 7-hydroxymitragynine through CYP3A enzymes, and 7-OH is detectable in people after oral kratom administration. Researchers disagree about how much of mitragynine’s animal antinociception is explained by that metabolite, which is a real scientific dispute rather than a reason to omit the finding.

These studies show why consumed leaf, purified mitragynine, and concentrated 7-OH can produce different exposures. They do not make an animal hot-plate result a treatment recommendation or establish that every commercial product behaves the same way.

What controlled human studies actually found

In 2022, six healthy adults drank a tea prepared from 2 grams of a chemically characterized dried-leaf product. Mitragynine, speciogynine, and paynantheine generally reached maximum measured blood concentrations sooner than three related alkaloids, while their terminal half-lives were longer. The study directly showed that multiple kratom alkaloids are orally absorbed and follow different concentration-time patterns in people.

In 2023, 12 healthy adults consumed the same amount of characterized kratom tea with probe medicines used to measure CYP3A and CYP2D6 activity. Kratom increased peak midazolam concentration by about 50% and total exposure by about 40%, while dextromethorphan exposure was essentially unchanged. The unchanged midazolam half-life pointed to inhibition of intestinal CYP3A during first-pass metabolism. That is a measured human drug-interaction signal, not merely a theoretical concern from a test tube.

A larger program administered encapsulated dried-leaf powder to healthy volunteers once and then daily for 15 days. Mitragynine and 7-OH blood concentrations increased with the administered amount. Median time to maximum concentration was roughly one to two hours, and repeated administration produced accumulation before steady-state concentrations were reached. The highest reported mean terminal half-life for mitragynine was longer after repeated administration than after a single administration. The program was paid for by the product company, and several authors disclosed company or industry consulting relationships.

The safety report from that 116-person randomized program found no deaths or serious adverse events during the trial. Short-term adverse events generally increased with the administered amount. Dizziness, nausea, and relaxation were most common after a single administration; headache, feeling hot, increased alanine aminotransferase, and nausea were among the most common after repeated administration. The authors reported no meaningful withdrawal or abuse-potential signal during their protocol. The result is useful short-term evidence for that dried-leaf product in screened healthy adults; it does not address years of use, uncommon events, higher-risk patients, or concentrated 7-OH products.

What people report experiencing and why they consume kratom

Surveys and interviews in the United States and Southeast Asia consistently show that people consume kratom for identifiable reasons. Common reports include energy or alertness, working through fatigue, pain relief, relaxation, mood, and attempting to reduce or stop opioids or other substances. Community studies in southern Thailand have documented work-related and social contexts around fresh-leaf use, while U.S. surveys more often involve powders, capsules, or extracts purchased commercially.

Reported effects can include stimulation or alertness, relaxation, analgesia, and sedation. Unwanted effects reported across surveys and clinical sources include nausea, vomiting, dizziness, constipation, sweating, dry mouth, rapid heartbeat, drowsiness, and loss of appetite. Regular users can develop tolerance, physical dependence, and withdrawal symptoms such as restlessness, muscle aches, insomnia, irritability, gastrointestinal distress, or depressed mood.

These findings establish that kratom has psychoactive and physiological effects in humans. The main uncertainty is not whether people feel anything; it is how often a specific effect occurs, how strongly it relates to amount and product composition, and which medical, medication, or polysubstance factors change risk.

Adverse events, dependence, and the limits of surveillance data

Poison-center calls, case reports, toxicology records, and adverse-event databases include agitation, sedation, seizures, liver injury, cardiovascular findings, respiratory depression, dependence, withdrawal, and deaths in which kratom compounds were detected. Many severe cases also involve other substances, an uncertain product, or incomplete exposure information. Those complications make attribution difficult, but they do not make the events irrelevant.

Dependence is supported by more than isolated case reports. Community and survey studies include people who describe tolerance, cravings, continued use despite problems, and withdrawal after stopping. Concentrated 7-OH products deserve separate attention because 7-OH is a more potent mu-opioid-receptor agonist than mitragynine; a 2025 clinical case documented rapid tolerance and severe substance use disorder involving a chemically confirmed semi-synthetic 7-OH film.

Surveillance records rarely reveal the total number of comparable exposures, so they cannot by themselves produce a reliable population-wide event rate. They are best used to identify the kinds of harm occurring and the product or polysubstance questions that controlled research needs to investigate.

Why leaf, MIT extracts, and enriched 7-OH can feel different

Fresh leaf and dried powder contain mitragynine plus many minor alkaloids, with naturally low 7-OH relative to mitragynine. Extracting or concentrating the leaf increases the amount of selected compounds in a smaller mass. Tablets, gummies, liquid shots, and extract powders can also change how quickly the material is consumed and how easily a person repeats an amount.

Enriched or semi-synthetic 7-OH products are a more significant departure from leaf. They deliver a compound with stronger mu-opioid-receptor activity at levels that can greatly exceed those naturally present in leaf. That distinction helps explain why treating every kratom-labeled product as one exposure obscures both effects and risks.

The product-types guide, quality and lab-testing guide, and COA guide explain how ingredient identity, amount, format, lot, and laboratory documents connect.

Why current 7-OH evidence matters

FDA’s 2025 assessment describes 7-OH as a potent mu-opioid-receptor agonist and focuses on products containing concentrated or enriched amounts. Animal research, receptor studies, clinical cases, poison data, and product testing collectively support treating those products as materially different from ordinary dried leaf.

In July 2026, DEA announced a temporary-scheduling action involving named 7-OH-related substances, followed by a Federal Register notice defining the operative scope and dates. The current documents are maintained on the DEA 7-OH scheduling tracker. The action concerns named substances; readers still need the actual ingredient identity and laboratory record to understand a product.

The biggest questions still unresolved

Whether a kratom-derived medicine can demonstrate effectiveness for pain, opioid use disorder, or another indication in adequate clinical trials.
How years of regular leaf or extract consumption affect the liver, cardiovascular system, hormones, cognition, and dependence risk across diverse populations.
How product concentration, minor alkaloids, food, genetics, medications, and other substances change effects and adverse events.
How often severe events occur relative to the number of people consuming comparable, chemically verified products.
Which withdrawal and substance-use-disorder interventions work best for people using leaf, extracts, or concentrated 7-OH.
Whether catalog colors or geography names predict reproducible chemical or human-effect differences after products are independently characterized.

What researchers are studying now

Active research spans product characterization, chemical variability, metabolism, human pharmacokinetics, interactions, tolerability, abuse-related measures, observational patterns, and methods for distinguishing compounds and products. Some questions concern whole botanical material; others concern isolated molecules. Those research programs should not be collapsed into one category.

In June 2026, NIH announced that an Investigational New Drug application for a purified mitragynine formulation had taken effect, allowing a first-in-human phase I program to proceed. The current ClinicalTrials.gov record for MG001 describes a randomized, double-blind, placebo-controlled single-ascending study in healthy volunteers, with a planned focus on safety, tolerability, and pharmacokinetics. Its dates are listed as estimates and may change.

This program studies a purified mitragynine formulation, not every kratom product. An IND allows clinical investigation; it is not FDA approval and does not demonstrate effectiveness. Results will need to be evaluated when available, using the actual protocol, participants, material, outcomes, and disclosures.

What stronger evidence would look like

Confidence grows when independent teams reach compatible findings with clearly identified materials and methods that can be examined or repeated. For kratom, that would include larger and more diverse participant groups, longer observation periods, validated product analysis, pre-specified outcomes, appropriate comparison groups, transparent reporting of exclusions and missing data, and publication of results whether they are favorable, unfavorable, or mixed.

Replication does not require every study to produce an identical number. Different populations, materials, or protocols may reasonably produce different estimates. The important question is whether those differences can be explained and whether the overall evidence converges. A single striking paper can change the questions researchers ask; it rarely settles a broad question by itself.

Evidence also becomes more useful when researchers preserve the connection between the tested material and the reported result. A chemical profile, batch record, preparation method, and stability record help later readers understand what was actually studied. Without that chain, even a carefully conducted human protocol can be difficult to compare with another study or a product outside the trial.

Evidence map at a glance

Question	Strongest current evidence	What it can establish	Major remaining limit
Plant identity	Taxonomy, authenticated specimens, complementary identity methods	The species and evidence supporting a sample identity	Processed materials can lose diagnostic features
Chemical composition	Validated analysis of a defined sample	Named compounds and amounts under the stated method	Results do not transfer automatically to another lot or format
Mechanisms	Receptor, metabolism, and animal studies	Mu-opioid activity, mitragynine-to-7-OH metabolism, antinociception, and gastrointestinal effects	Animal and isolated-compound results do not quantify effects in people
Human pharmacokinetics	Controlled oral-administration studies	Absorption, time to peak concentration, half-life, accumulation, and a CYP3A interaction	Small or screened samples and product-specific protocols
Short-term tolerability	Randomized dried-leaf study	Dizziness, nausea, relaxation, headache, feeling hot, and other events during the trial	Long-term and uncommon outcomes remain unresolved
Real-world experience	Surveys, community studies, surveillance, and case records	Energy, pain, relaxation, withdrawal management, adverse effects, dependence, and severe-event signals	Self-selection, product verification, other substances, and missing denominator data

How this evidence map should change over time

A responsible synthesis is revisable. New human studies may strengthen, narrow, or contradict an earlier interpretation. Trial records may change status. Analytical assignments may be corrected. Agency actions may add new dates or scope. The review date should therefore remain visible, and meaningful revisions should be recorded rather than silently blended into older copy.

When a new claim appears, identify the exact material and question, open the complete source, examine the methods and disclosures, and compare it with independent evidence. How to Evaluate Kratom Information Online provides the complete verification framework.

Sources and further reading

Written By : Kratom Paradise Editorial Team